Only three GLP-1 drugs are FDA-approved specifically for chronic weight management in people without diabetes: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide), plus the oral Wegovy semaglutide pill
Suchankova P, Yan J, Schwandt ML, et al
If you are unable to keep fluids down, contact your study team, GP, or NHS 111 promptly
Yin L, Deng Z, Liu J, Ye L, Huang J, Dai Y, et al
However, if acid reflux becomes severe, affects daily life, or leads to complications such as difficulty swallowing, chronic cough, or chest pain, stopping the medication may be necessary
Semaglutide activates GLP-1 receptors in the brain to reduce hunger and slow stomach emptying, yet some patients experience plateaus or minimal weight loss within the first 8 to 12 weeks of therapy